Incyte — Jul 28, 2026 release

Opzelura Financial Impact Related to Agreement with CMS As a result of the agreement with CMS, * the total estimated incremental impact on Opzelura net sales for the full year 2026 is $300 - $310 million which includes the reversal of previously established accrual balances through the first quarter of 2026 and effects of an improved gross-to-net (GTN) profile on a go-forward basis as summarized in the table below. Opzelura Net Sales 1 Total estimated incremental impact on Opzelura net sales for the full year 2026 $300 - $310 million One-time, non-cash benefit of the reversal of previously established accrued balances through the first quarter of 2026 ending March 31, 2026 $246 million Impact on second quarter of 2026 net sales resulting in improved GTN $15 million Estimated impact on third and fourth quarters of 2026 net sales from improved GTN $40 - $50 million 1 Totals may not add due to rounding. 2026 Financial Guidance Incyte is raising its full year 2026 total net sales guidance to $5,130 - $5,260 million, reflecting the impact of the agreement with CMS related to the Opzelura line extension, * as well as the continued strong performance of its Hematology and Oncology growth products, including Niktimvo, Monjuvi/Minjuvi and Zynyz. Incyte is raising its full year 2026 Opzelura net sales guidance to $1,050 - $1,100 million and full year 2026 Hematology and Oncology net sales guidance to $860 - $890 million. Incyte is also raising its full year 2026 operating expense guidance. Total GAAP R&D and SG&A operating expense guidance is $4,915 - $4,995 million and total non-GAAP R&D and SG&A operating expense guidance is $4,625 - $4,695 million. The revised guidance reflects the impact of the acquisition of Vega T